Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib in Relapsed or Refractory DLBCL
NCT01499303Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2011
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of fostamatinib in diffuse large B-cell lymphoma (DLBCL), sponsored by AstraZeneca. Started Dec 2011; status: completed.
02
Drugs
fostamatinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01499303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01499303.